A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis

British Journal of Dermatology

Volumn 142, Issue 1, 2000, Pages 97-102

  Havu, V ^a   Heikkila H ^b   Kuokkanen, K ^c   Nuutinen, M ^d   Rantanen, T ^e   Saari, S ^f   Stubb, S ^b   Suhonen, R ^g   Turjanmaa, K ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d Novartis Finland Oy   (Finland)

^e PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^f Laakariasema Pulssi   (Finland)

^g MIKKELI CENTRAL HOSPITAL   (Finland)

Author keywords

Diflucan ; Fluconazole; Lamisil ; Onychomycosis; Terbinafine

Indexed keywords

FLUCONAZOLE; TERBINAFINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONYCHOMYCOSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SKIN MANIFESTATION; TASTE DISORDER;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FLUCONAZOLE; HUMANS; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 0033977640     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03247.x     Document Type: Article

References (33)

1. Drake LA. Impact of onychomycosis on quality of life. J Am Podiatry Med Assoc 1997; 87: 507-11.
2. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 (Suppl. 43): 15.
3. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl. 39): 23-7.
4. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
5. Charif MA, Elewski BE. Prevalence of onychomycosis in the United States: results of a population based survey (Abstr. 521). Presented at the 1996 Annual Meeting of the Society for Investigative Dermatology, Washington DC, May 1-5, 1996.
6. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98-100.
7. Evans EGV. The clinical efficacy of terbinafine in the treatment of fungal infections of the skin. Rev Contemp Pharmacother 1997; 8: 325-41.
8. Roberts DT. The clinical efficacy of terbinafine in the treatment of fungal infections of the nails. Rev Contemp Pharmacother 1997; 8: 299-312.
9. De Cuyper C. Long term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996; 135: 156-7.
10. Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-5.
11. Watson AB, Marley JE, Ellis DH, Williams TG. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775-9.
12. Watson AB, Marley JE, Ellis DH, Williams TG. Long-term follow up of patients with toenail onychomycosis after treatment with terbinafine. Australas J Dermatol 1998; 39: 29-30.
13. Goodfield MJD, Andrew L, Evans EGV. Short-term treatment of dermatophyte onychomycosis with terbinafine. Br Med J 1992; 304: 1151-4.
14. Faergemann J, Anderson C, Hersle K et al. Double blind, parallel group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750-3.
15. Haneke E, Tausch I, Bräutigam M et al. Short duration treatment of fingernail dermatophytosis: a randomized double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-7.
16. Hofmann H, Bräutigam M, Weidinger G et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-22.
17. Bräutigam M, Nolting S, Schopf RE, Weidinger G, for the Seventh Lamisil German Onychomycosis Study Group. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995; 311: 919-22.
18. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs itraconazole 200 mg/day: a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16-17.
19. Wildfeuer A, Seidl HP. Comparison of the in vitro activity of fluconazole against Candida albicans and dermatophytes. Arzneimittelforschung 1995; 45: 819-21.
20. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3: 115-17.
21. Fräki JE, Heikkilä HT, Kero MO et al. An open label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for the treatment of onychomycosis. Curr Ther Res 1997; 58: 481-91.
22. Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35: 587-8.
23. Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995; 33: 259-60.
24. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996; 41: 319-23.
25. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997; 133: 1213-19.
26. Suhonen R, Neuvonen PJ. The tolerability profile of terbinafine. Rev Contemp Pharmacother 1997; 8: 373-86.
27. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275-87.
28. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-6.
29. Schatz F, Bräutigam M, Dobrowolski E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-83.
30. Novick NL. Current therapy of onychomycosis: promoting patient compliance for successful treatment outcomes. J Geriatr Dermatol 1997; 5: 181-4.
31. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycosis in toenails with fluconazole 150 mg weekly. Acta Derm Venereol (Stockh) 1996; 76: 219-21.
32. Scher RK, Breneman D, Rich P et al. Once weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Dermatol 1998; 38 (Suppl.): S77-86.
33. Evans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent intraconazole in treatment of toenail onychomycosis. Br Med J 1999; 318: 1031-5.